Given the pivotal role of tumor necrosis factor (TNF) in the immune system, the use of infliximab and analogous biologics may elevate the risk of infections such as tuberculosis and hepatitis B. Consequently, patients must undergo screening for these infections prior to initiating treatment, and live vaccines should be avoided throughout the course of therapy [17]. Here, TNF is linked to hepatitis B virus infection.